Nine One Capital

Further Work on Venus Remedies: The Etimicin Opportunity

A decade-old, Phase-III-validated antibiotic may be more relevant today than the market assumes

Dec 6 • 

Nine One Capital

16

4

November 2025

Quarterly Update: Process, Survival & the Path Ahead

How we are protecting capital, staying invested, and preparing early for the next small–microcap upcycle.

Nov 30 • 

Nine One Capital

37

3

The Trouble With Buying Great Narratives at Great Prices

The price you pay shapes your return, not the story you are sold

Nov 26 • 

Nine One Capital

9

1

CWD: Hyper-Growth Phase Begins

From concept to execution: CWD enters its hyper-growth phase

Nov 16 • 

Nine One Capital

8

Venues Remedies Q2 FY26 Results

Numbers starting to make sense

Nov 10 • 

Nine One Capital

7

1

When One Fraud Raised Questions on 15 Other Listed Companies

The auditor, the merchant banker, and the web that links them. A real case from our forensic research

Nov 8 • 

Nine One Capital

27

2

11

October 2025

Rare Earths: Positioning Early for the Next Strategic Mining Wave

A strategic rebalancing is underway in rare earth supply chains. Our in-depth client report identifies India’s emerging role and the listed businesses…

Oct 26 • 

Nine One Capital

19

3

4

Eimco Elecon: A Clean Slate with Optionality Ahead

Can a promoter exit, strong balance sheet, and new verticals set the stage for the next phase of growth

Oct 14 • 

Nine One Capital

11

1

2

September 2025

How to Analyse a 100 PE Stock

Virtuoso as a case study in looking beyond trailing multiples and building forward scenarios to understand the downside/ upside potential

Sep 24 • 

Nine One Capital

20

2

3

AI Can Read, It Can’t Infer

Case of an engineering company where filings revealed super high growth the market is completely missing

Sep 17 • 

Nine One Capital

13

2

1

Preparing, Not Predicting

How we are positioning in small and micro caps before the tide turns

Sep 2 • 

Nine One Capital

13

1

August 2025

Supreme Court’s Stray Dog Ruling: A ₹20 Billion Tailwind for Animal Health Stocks?

Why a public health mandate could quietly reshape India’s animal health market, and what investors should watch.

Aug 25 • 

Nine One Capital

11

2